Novo Nordisk stock news
On August 31, 2026, Novo Nordisk (NVO) faced a series of analyst rating downgrades following a 9% decline in share price over the preceding month. Despite reporting volume growth for the Wegovy pill in the second quarter, the actual sales figures significantly underperformed market expectations, raising concerns about the company's ability to meet its full--year 2026 guidance of 0% to --6% sales growth. Investors are now pivoting their focus toward the fourth quarter of 2026, when the U.S. FDA is expected to issue a decision on CagriSema, a next--generation obesity treatment. Clinical data for CagriSema has shown a 22.7% mean weight loss, positioning it as a critical asset for Novo Nordisk to counter intensifying competition from Eli Lilly’s tirzepatide franchise.